Skip to main content

Table 4 Lung involvement

From: Janus kinase inhibitors vs. abatacept about safety and efficacy for patients with rheumatoid arthritis-associated interstitial lung disease: a retrospective nested case-control study

 

Occurrence

Lung involvement

ABT (n = 21)

3 (14.3%)

Pneumonia (n = 2)

Empyema (n = 1)

JAKi (n = 21)

2 (9.5%)

Influenza pneumonia (n = 1)

Organized pneumonia (n = 1)

  1. ABT: abatacept; JAKi: Janus kinase inhibitors
Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us